Showing results 2 to 5 of 5
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Reduced changes in bone mineral density in Chronic HBV (CHB) Patients receiving Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF) Proceeding/Conference:The Liver MeetingĀ® 2016 | 2016 | ||
Reduced changes in bone mineral density in chronic hepatitis B patients receiving TAF compared with TDF Proceeding/Conference:Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017 | 2017 | ||
RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology | 2018 | ||
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology | 2018 |